High-dose Alemtuzumab-Cyclosporine vs Tacrolimus-Methotrexate-Sirolimus for Chronic Graft-versus-Host Disease Prevention.
Holtzman NG, Curtis LM, Salit RB, Shaffer BC, Pirsl F, Ostojic A, Steinberg SM, Schulz E, Wilder JS, Hughes TE, Rose J, Memon S, Korngold R, Gea-Banacloche J, Fowler DH, Hakim FT, Gress RE, Bishop MR, Pavletic SZ.
Holtzman NG, et al. Among authors: curtis lm.
Blood Adv. 2024 Apr 26:bloodadvances.2023010973. doi: 10.1182/bloodadvances.2023010973. Online ahead of print.
Blood Adv. 2024.
PMID: 38669315
However, increased infections and relapse resulted in a lack of survival benefit after long-term follow-up. ClinicalTrials.gov identifier: NCT00520130....
However, increased infections and relapse resulted in a lack of survival benefit after long-term follow-up. ClinicalTrials.gov identi …